ArticleProceedings of the National Academy of Sciences of the United States of America1997
Direct evidence to support the role of HLA-G in protecting the fetus from maternal uterine natural killer cytolysis.
Article in Proceedings of the National Academy of Sciences of the United States of America, 1997. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 196 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
196 citing papers in PubMed, 1 synthesis or guideline pooled it, 691 citations in OpenAlex.
- Biomarker role of maternal soluble human leukocyte antigen G in pre-eclampsia: A meta-analysis.Immunity, inflammation and disease · 2024Pooled it
- HLA-G expression in acute lymphoblastic leukemia: a significant prognostic tumor biomarker.Medical oncology (Northwood, London, England) · 2013Trial
- Immune checkpoints and immunoregulation in metabolic diseases and cancers: pathological mechanisms and therapeutic potential.Signal transduction and targeted therapy · 2026Review
- Article
- Placental Mesenchymal Stem Cell-Derived Extracellular Vesicles (PMSC-EVs) as an Innovative Therapy for Diabetic Wound Healing.International journal of molecular sciences · 2026Review
- Innate immunity and hypertension: unveiling inflammatory pathways for novel therapies.Frontiers in pharmacology · 2026Review
- Cannabidiol (CBD) as a novel inhibitor of HLA-G expression in human choriocarcinoma cell line (JEG-3).Scientific reports · 2025Article
- Hypoimmune stem cells and islets: hype or a true breakthrough in diabetes treatment?Cellular & molecular biology letters · 2025Review
- Immune evasion strategies in AFP-producing gastric carcinoma: characterized by HLA-G expression and HLA class I deficiency.Virchows Archiv : an international journal of pathology · 2025Article
- Is the vIL-10 Protein from Cytomegalovirus Associated with the Potential Development of Acute Lymphoblastic Leukemia?Viruses · 2025Review
- Targeting archetypes of viral-driven cancers with immunotherapy: a perspective on immunogenicity within the tumor microenvironment.Frontiers in immunology · 2025Review
- Harnessing the immunomodulatory properties of HLA-G for advanced immunotherapies.Frontiers in immunology · 2025Review
- Advancements and Challenges in Immune Protection Strategies for Islet Transplantation.Journal of diabetes · 2025Review
- Article
- HLA-G neo-expression modifies genetic programs governing tumor cell lines.Cancer immunology, immunotherapy : CII · 2024Article
- Strategies for Overcoming Immune Evasion in Bladder Cancer.International journal of molecular sciences · 2024Review
- Analogies between HPV Behavior in Oral and Vaginal Cavity: Narrative Review on the Current Evidence in the Literature.Journal of clinical medicine · 2024Review
- Harnessing the potential of HLA-G in cancer therapy: advances, challenges, and prospects.Journal of translational medicine · 2024Review
- Immunologic aspects of preeclampsia.AJOG global reports · 2024Review
- The Biological Significance of Trogocytosis.Results and problems in cell differentiation · 2024Article
136 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
HLA-G is a nonclassical major histocompatibility complex class I molecule selectively expressed on cytotrophoblasts at the feto-maternal interface, where it may play an important role in maternal tolerance of the fetus. We provide direct evidence under physiological conditions that supports the role of HLA-G in protecting cytotrophoblasts against natural killer (NK) cytolysis in 6 semiallogenic combinations of maternal uterine NK cells and their own trophoblast counterparts, as well as in 20 allogenic combinations of maternal uterine NK cells and trophoblasts from different mothers. We show that, in all cases studied, this HLA-G-mediated protection was abolished by treatment of cytotrophoblasts with an HLA-G-specific mAb. The HLA class I-negative K562 cell line transfected with the predominant HLA-G1 isoform results in similar protection and abolition from maternal uterine NK lysis. Because maternal uterine NK cells express killer inhibitory receptors for HLA-G, we conclude that their interactions contribute to the survival of the fetal semiallograft by confering immunological tolerance to its tissues.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.